Bydureon

Active Ingredient(s): Exenatide
FDA Approved: * January 27, 2012
Pharm Company: * AMYLIN
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Bydureon Overview

Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day.[1] A once-weekly injection has been approved ...

Read more Bydureon Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Byetta

Recent Bydureon Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Exenatide
  • For Suspension, Extended Release: 2mg, 2mg/vial
  • Injection: 2mg, 300mcg/1.2ml (250mcg/ml), 300ugm/1.2ml (250ugm/ml), 300ugm/1.2ml(250ugm/ml), 600mcg/2.4ml (250mcg/ml), 600ugm/2.4ml (250ugm/ml), 600ugm/2.4ml(250ugm/ml)
  • Suspension, Extended Release: 2mg/0.85ml (2mg/0.85ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Bydureon: (4 results)

Sorted by National Drug Code
  • 0310-6520 Bydureon Kit by Astrazeneca Pharmaceuticals Lp
  • 0310-6530 Bydureon 2 mg/.65ml Subcutaneous Injection, Suspension, Extended Release by Astrazeneca Pharmaceuticals Lp
  • 66780-219 Bydureon Kit by Amylin Pharmaceuticals, LLC
  • 66780-226 Bydureon Kit by Amylin Pharmaceuticals, LLC

Other drugs which contain Exenatide or a similar ingredient: (3 results)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA